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Abstract
Background: Previously reported associations between vitamin D status, as measured by serum 25-hydroxyvitamin
D [25(OH)D] concentrations, and cardiometabolic risk factors were largely limited by variability in 25(OH)D assay
performance. In accordance with the Vitamin D Standardization Program, serum 25(OH)D measurement was recently
standardized in the National Health and Nutrition Examination Survey (NHANES) to reduce laboratory and method
related differences in serum 25(OH)D results. We evaluated the overall and ethnic-specific associations between the
newly standardized serum 25(OH)D concentrations and cardiometabolic risk in U.S. adults.
Methods: This study examined standardized 25(OH)D data from five cycles of the NHANES (2001–2010). The
total sample included 7674 participants (1794 Mexican-Americans, 4289 non-Hispanic whites, and 1591 non-
Hispanic blacks) aged ≥ 20 years who were examined in the morning after overnight fasting. Serum 25(OH)D
was directly measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in 2007–2010, and
was predicted from LC-MS/MS equivalents for 2001–2006. Serum 25(OH)D levels were categorized into quartiles (<43.4,
43.4–58.6, 58.7–74.2, ≥74.3 nmol/L). Cardiometabolic risk was defined by the homeostatic model assessment of insulin
resistance (HOMA-IR), metabolic syndrome (MetS), and Framingham cardiovascular disease (CVD) risk. Prevalence ratios
and 95% confidence intervals were calculated using modified Poisson regression.
Results: After full adjustment for confounders, serum 25(OH)D ≥74.3 nmol/L was associated with lower cardiometabolic
risk compared to 25(OH)D <43.4 nmol/L in the overall sample [HOMA-IR: 0.70 (0.59, 0.84); MetS: 0.82 (0.74, 0.91); CVD risk:
0.78 (0.66, 0.91)]. These associations remained significant in Mexican-Americans [HOMA-IR: 0.54 (0.35, 0.82); MetS: 0.73 (0.
55, 0.96)], non-Hispanic whites [HOMA-IR: 0.81 (0.68, 0.96); MetS: 0.84 (0.73, 0.95); CVD risk: 0.78 (0.64, 0.93)]; and in non-
Hispanic blacks [HOMA-IR: 0.67 (0.45, 0.99); MetS: 0.75 (0.56, 0.97); CVD risk: 0.58 (0.41, 0.81)].
Conclusions: Low vitamin D status is a significant risk factor for cardiometabolic disease in U.S. adults based
on standardized serum 25(OH)D results, irrespective of ethnic background. Future studies using standardized
25(OH)D data are needed to confirm these results, particularly amongst U.S. blacks with 25(OH)D concentrations above
75 nmol/L.
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Background
A role in the renin-angiotensin aldosterone system
(RAAS) and extensive immunomodulatory properties have
identified vitamin D as a potential modifiable risk factor in
cardiometabolic disorders [1–3]. Measurement of vitamin
D status is based on circulating total 25-hydroxyvitamin D
[25(OH)D] concentrations, which reflect both food intake
and endogenous production of vitamin D. Low serum
25(OH)D levels have been linked to a range of non-
skeletal health conditions in adults, including metabolic
disorders and cardiovascular diseases [4–8]. In addition,
vitamin D is thought to play a protective role against the
development of type-2 diabetes by improving the insulin
secretion of pancreatic beta cells and by maintaining
glucose homeostasis [9–13]. However, studies investigating
the relation between vitamin D status and cardiometabolic
disorders are inconsistent [14–17]. Among the possible
explanations for this discrepancy include the substantial
heterogeneity among definitions for vitamin D deficiency,
different age and ethnic distributions, and large variations
in the performance of serum 25(OH)D assays.
Previous analyses of the NHANES have relied on unstan-
dardized serum 25(OH)D measured by the Diasorin radio-
immunoassay (RIA) kit, a method that has been criticized
for its lack of precision and documented bias [18, 19]. In
accordance with the vitamin D Standardization Program
(VDSP), the National Center for Health Statistics (NCHS)
of the Centers for Disease Control and Prevention (CDC)
recently released the standardized serum 25(OH)D data
files in October, 2015 [20]. The standardized 25(OH)D data
provide the most reliable estimates of serum 25(OH)D
concentrations using the ultra-high performance liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
method [21]. The LC-MS/MS method has improved sensi-
tivity and specificity for serum 25(OH)D metabolites com-
pared to previous immunoassay methods, and the
standardization of serum 25(OH)D data allows for com-
parison across different survey cycles of the NHANES,
providing sufficient power to study risk associated with
varying concentrations of serum 25(OH)D. Thus, pre-
viously reported associations between serum 25(OH)D
with cardiometabolic disorders using unstandardized
serum 25(OH)D data from previous cycles of NHANES
(1988–1994, and 2001–2006) were likely affected by
method-related variations in serum 25(OH)D assays.
In addition to the assay-related differences in serum
25(OH)D results, ethnic variations in the relationship
between vitamin D status and cardiometabolic disorders
have been documented, with mixed results. For example,
ethnic-specific differences in diabetes risk by serum
25(OH)D status have been confirmed in previous
NHANES cycles (1988–1994, and 2001–2006), where an
inverse relationship between unstandardized 25(OH)D
concentrations and type-2 diabetes risk was observed in
Mexican-Americans and non-Hispanic whites, but not
in non-Hispanic blacks [22, 23]. Similarly, 25(OH)D
concentrations were significantly associated with fatal
stroke and heart failure in NHANES III, with increased
risk seen in white participants with low 25(OH)D, but
not in black participants [24]. Finally, in a prospective
study, an increased risk of coronary heart disease events
was reported in white or Chinese participants with low
serum 25(OH)D, but not in blacks or Hispanics [25].
Previous analyses using unstandardized data were
likely confounded by large variations in serum 25(OH)D
results, and ethnic-specific analyses were further con-
strained by small sample sizes in underrepresented pop-
ulations, such as U.S. blacks, adding more uncertainty to
these estimates. Accurate assessment of the overall and
ethnic-specific variations in vitamin D is therefore cru-
cial, and dependent upon the use of standardized data
with sufficient statistical power to examine ethnic differ-
ences in the relationship between vitamin D status and
cardiometabolic risk. Thus, the purpose of this study
was to provide a comprehensive assessment of cardio-
metabolic risk including insulin resistance, metabolic
syndrome, and cardiovascular disease risk in relation to
serum 25(OH)D levels in U.S. adults, and to estimate the
ethnic-specific associations using the newly standardized
serum 25(OH)D data from NHANES 2001–2010.
Subjects and methods
Participants
Conducted by the NCHS, NHANES is a series of strati-
fied, multistage probability surveys designed to collect
cross-sectional data on the health and nutritional status
of the civilian, non-institutionalized U.S. population.
NHANES is an ongoing survey and data are reported in
2-year intervals, which are available for public use [26].
NHANES oversamples certain under-represented groups
in the population, including Mexican Americans, blacks,
older adults and those of lower socioeconomic status.
Each survey cycle consists of an in-home interview,
physical examinations and laboratory tests. Descriptions
of the standardized protocols used for data handling
during the interview, laboratory, and physical examina-
tions have been previously published [27].
We initially identified 23,968 adults ≥20 years with avail-
able standardized serum 25(OH)D data from 2001–2010.
We excluded 10,939 participants who fasted < 8 h, 466
pregnant women, 1355 participants in “other Hispanic” or
“other race” category, 73 with serum albumin < 2.9 g/dL,
1081 with estimated glomerular filtration rate (eGFR)
< 60 mL/min/1.73 m2, and 2380 participants with
missing covariate information. Those in the “other
Hispanic” category were excluded due to a change in
the 2007–2010 NHANES sampling design, where His-
panics were oversampled instead of only the Mexican-
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American population [28]. As such, we only included
those in the “Mexican-American” category. The final
analytical sample included 7674 adults ≥20 years who
fasted for ≥ 8 h and self-identified themselves as Mexican-
American (MA), non-Hispanic white (NH-white), or non-
Hispanic black (NH-black). A flowchart for study sample
derivation is shown in Fig. 1. NHANES was approved by
the NCHS institutional board and all adults provided writ-
ten informed consent [29].
Measurement of serum 25(OH)D
For 2007–2010, serum 25(OH)D metabolites were ana-
lyzed by the CDC laboratory using the LC-MS/MS
method and total serum 25(OH)D (nmol/L) was calcu-
lated as the sum of 25(OH)D3 and 25(OH)D2, excluding
the C3-epi-25(OH)D3 metabolite. For 2001–2006, serum
25(OH)D levels were initially measured using the
Diasorin RIA kit (Stillwater, MN); however, due to con-
cerns about bias and imprecision for the Diasorin RIA
assay, the CDC developed regression equations to con-
vert RIA values to LC-MS/MS equivalents for NHANES
1988–1994 and 2001–2006 [30]. In order to combine
serum 25(OH)D measurements, we used the predicted
LC-MS/MS equivalent total serum 25(OH)D data from




Insulin resistance was estimated by the homeostatic
model assessment-insulin resistance index (HOMA-IR),
calculated as the product of the fasting insulin concentra-
tion (μU/ml) and the fasting plasma glucose concentration
(mmol/L), divided by 22.5 [31]. We defined insulin resist-
ance as HOMA-IR ≥ 75th percentile (sex- and ethnic-
specific). Fasting glucose concentrations were measured
by a Hexokinase enzymatic method, and serum insulin
concentrations were measured by a radioimmunoassay in
2001–2002, a two-site immunoenzymometric method in
2003–2004 and an ELISA two-site enzyme immunoassay
method in 2005–2010.
Metabolic syndrome
We used the revised U.S. National Cholesterol Education
Program Adult Treatment Panel III (NCEP/ATPIII) report
to define MetS [32] as 3 or more of the following 5 cri-
teria: 1) waist circumference (WC) ≥ 102 cm in men or ≥
88 cm in women; 2) triglycerides ≥ 1.7 mmol/L or medica-
tion; 3) high density lipid (HDL) cholesterol < 1.0 mmol/L
in men or < 1.3 mmol/L in women or medication; 4) blood
pressure (BP) ≥ 130/85 mmHg or treatment for hyperten-
sion; 5) fasting blood glucose ≥ 5.6 mmol/L or treatment
for diabetes. WC and BP data were collected during phys-
ical examinations and descriptions of the standardized
protocol are provided in the NHANES Anthropometry
Procedures Manual [33]. Up to four BP readings were ob-
tained during the physical examination and the average
BP was estimated using the BP protocol provided by
NHANES [34]. Triglycerides were measured enzymatically
Fig. 1 Flowchart showing the exclusion criteria for sample derivation,
NHANES 2001–2010
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in serum samples from the morning session. HDL-
cholesterol was measured using either the Heparin man-
ganese precipitation method or a direct HDL-cholesterol
immunoassay method. Prescription medication use was
self-reported during the in-home interview. Using the
standardized generic prescription drug codes, medication
use was classified into four drug categories; HDL-specific
medications, lipid medications, anti-hypertensive medica-
tions, and anti-hyperglycemic medications.
Framingham CVD Risk
The Framingham CVD risk score was used to estimate
the 10-year composite risk for coronary heart disease,
stroke, peripheral artery disease, and heart failure [35].
In the first step of the algorithm, point scores for age,
sex, total and HDL cholesterol, SBP, treatment of hyper-
tension, smoking, and diabetes status were assigned [35].
CVD risk scores were subsequently computed for each
participant based on age- and sex-specific criteria (range
for men: −3 to ≥ 18; women: −3 to ≥ 21), which were
then translated into a participant’s absolute 10-year risk
for a CVD event. The specific details on the point scores
for the CVD risk algorithm is provided in Tables five-
eight in reference [35]. In our study, an absolute risk of ≥
15% was defined as “high” and an absolute risk of < 15%
as “low” for 10-year predicted risk. These cutoffs were
calibrated to approximate the absolute CVD risk associ-
ated with insulin resistance (12.6%) and MetS (14.9%) in
our study sample.
Total cholesterol was measured enzymatically at Johns
Hopkins lipid laboratory (Baltimore, MD). Treatment of
hypertension was established from self-reported anti-
hypertensive medications. Smoking status (0 = non-
smokers, 1 = current smokers) was self-reported during
the in-home interview. Diabetes status was defined as a
fasting glucose ≥ 126 mg/dL (7.0 mmol/L) or current use
of diabetes medication.
Confounders
Age, sex, ethnicity, smoking status, educational attain-
ment, physical activity (PA), dietary supplement intake
and use of medications were self-reported by question-
naire during the in-home interview. Educational attain-
ment was categorized as less than high school, high
school graduate, and some college or college graduate or
higher. The PA questionnaire included a series of ques-
tions related to participant’s daily activities, leisure-time
activities, and sedentary activities at home. Participants
self-reported the number of days in the past month or in
a typical week they engaged in daily and leisure time
activities and the average duration for these activities. A
metabolic equivalent (MET) of 4.0 for moderate, and 8.0
for vigorous intensity PA were used to estimate the
MET minutes/week for each participant. Supplemental
intake of vitamin D for 2007–2010 was obtained from
24-h dietary recall, and total daily vitamin D intake was
estimated across all supplement sources for 2001–2006.
Vitamin D supplementation was categorized as “any” ver-
sus “nonusers”. Season corresponds to season of blood
draw, which was reported by NHANES as winter months
(November–April) and summer months (May–October).
Standing height and weight were measured during the
physical examination and were used to calculate body
mass index (BMI: kg/m2).
Statistical analysis
For descriptive statistics, weighted means for continuous
variables and weighted percentages for categorical vari-
ables along with 95% confidence intervals (CIs) were
used. Differences in descriptive statistics across ethnic
groups were assessed by survey-weighted Wald-F-Test
and Chi-square tests to examine the independence of
means and frequencies, respectively.
Modified Poisson regression models with robust error
variances were used to estimate the prevalence ratios (PRs)
and 95% CIs for cohort studies [36, 37]. Serum 25(OH)D
concentrations were categorized into quartiles (<43.4, 43.4–
58.6, 58.7–74.2, ≥74.3 nmol/L). To calculate the PRs for
each outcome, the lowest 25(OH)D quartile (<43.4 nmol/L)
was considered as the referent group (PR = 1.00). The
models were adjusted for confounders such as age, sex,
ethnicity, education, season of blood draw (winter, sum-
mer), survey cycle (corresponding to survey year), BMI,
vitamin D supplement use, smoking, total PA and relevant
medication use (lipid-lowering and anti-hyperglycemic
medications). The adjustment of these confounders in the
models were based on the association of the confounder
variables with both the outcome measures and serum
25(OH)D levels. Pairwise interactions with ethnicity and
age were explored by including the product terms in the
models (i.e. 25(OH)D*ethnicity and 25(OH)D*age). Models
for insulin resistance, MetS, and CVD risk were subse-
quently stratified by ethnicity, and the CVD risk model was
further stratified by age groups (i.e. 20–59 and ≥ 60 years).
To explore the possibility of differential bias by comorbid
conditions, a series of sensitivity analyses were conducted
after the exclusion of participants with physician diagnosed
diabetes and CVD (congestive heart failure, coronary hearts
disease, angina, heart attack, and stroke), and relevant
medication use (i.e. lipid, blood pressure, and anti-
hyperglycemic medications).
To ensure the representativeness of the data, clinical
fasting weights were applied to account for survey clus-
ter design, oversampling, and nonresponse. Statistical
analysis was performed using SAS 9.4 (Cary, NC) survey
procedures, which appropriately accounted for cluster
sampling and the complex sample design of NHANES.
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Baseline characteristics of the participants are shown in
Table 1. Overall, the mean age of the sample was 45.3
(44.7, 45.9), and the majority of the sample was NH-
white (55.9% NH-white, 23.4% MA, and 20.7% NH-
black). Of the 7674 participants, 22.5% (21.0, 24.1) were
taking vitamin D supplements, with supplement use
significantly higher in NH-whites [24.8% (22.8, 26.7)]
compared to MAs [13.0% (11.0, 15.0)] and NH-blacks
[14.7% (12.1, 17.3)]. The prevalence of MetS in the total
sample was 36.1% (34.6, 37.6), and NH-whites had the
highest prevalence of MetS [36.9% (35.0, 38.8)] com-
pared to MAs [34.8% (31.5, 38.1)] and NH-blacks
[31.6% (29.0, 34.0)]. The absolute CVD risk in the total
sample was 7.92% (7.63, 8.20), and NH-Whites had sig-
nificantly higher absolute CVD risk [8.26% (7.93, 8.59)]
compared to MAs [5.85% (5.40, 6.31)] and NH-blacks
[7.19% (6.77, 7.61)].
Serum 25(OH)D and HOMA-IR
The adjusted PRs for cardiometabolic risk by 25(OH)D
quartiles in the total sample are shown in Table 2. After
adjusting for age, sex, BMI, PA, ethnicity, season, survey
cycle, education, smoking, and use of vitamin D supple-
ment, lipid-lowering and anti-hyperglycemic medica-
tions, the highest 25(OH)D quartile (≥74.3 nmol/L) had
a 30% relative risk reduction in HOMA-IR [0.70 (0.59,
0.84)] compared to those in the lowest quartile
(<43.4 nmol/L). The associations remained significant
across all ethnic groups (Table 3). The highest relative
risk reduction was observed in MAs [0.54 (0.35, 0.82)],
followed by NH-blacks [0.67 (0.45, 0.99), and NH-whites
[0.81 (0.68, 0.96)] with serum 25(OH)D ≥74.3 nmol/L
compared to the lowest 25(OH)D quartile (<43.4 nmol/L).
Serum 25(OH)D and MetS
Overall, serum 25(OH)D levels ≥74.3 nmol/L were asso-
ciated with a 18% risk reduction in MetS [0.82 (0.74,
0.91)] compared to the lowest 25(OH)D quartile
(Table 2). The association of serum 25(OH)D with MetS
remained significant across all ethnic-groups (Table 3).
For MAs, the second 25(OH)D quartile (Q2: 43.4–
Table 1 Population Characteristics of U.S. Adults (≥20 years) in NHANES 2001–2010







Age (years) 45.3 44.7, 45.9 38.7 37.8, 39.6 46.6 45.9, 47.3 41.7 40.9, 42.6 <0.0001
BMI (kg/m2) 28.5 28.3, 28.6 28.8 28.5, 29.2 28.2 27.9, 28.4 30.1 29.7, 30.5 <0.0001
WC (cm) 97.7 97.3, 98.2 97.1 96.2, 98.0 97.8 97.2, 98.3 98.3 97.3, 99.3 0.225
25(OH)D (nmol/L) 65.5 64.2, 66.9 53.9 52.4, 55.4 70.2 68.9, 71.5 42.2 40.3, 44.0 <0.0001
Winter a 59.4 57.6, 61.3 52.3 50.6, 54.0 65.8 63.9, 67.8 39.8 38.2, 41.3 <0.0001
Summer b 69.4 67.9, 70.9 58.4 55.8, 60.9 72.3 70.8, 73.8 44.9 41.8, 48.1 <0.0001
Supplement nonusers 62.5 61.0, 64.0 52.9 51.3, 54.4 67.4 65.9, 69.0 39.9 38.1, 41.7 <0.0001
Supplement users 75.9 74.2, 77.5 60.5 58.2, 62.7 78.5 76.9, 80.2 55.4 50.8, 59.9 <0.0001
Vitamin D Supplement Use (%) 22.5 21.0, 24.1 13 11.0, 15.0 24.8 22.8, 26.7 14.7 12.1, 17.3 <0.0001
HOMAIR 3.06 2.97, 3.16 3.76 3.52, 4.00 2.93 2.81, 3.05 3.4 3.20, 3.59 <0.0001
MetS (%) 36.1 34.6, 37.6 34.8 31.5, 38.1 36.9 35.0, 38.8 31.6 29.0, 34.0 <0.01
Absolute CVD risk (%) 7.92 7.63, 8.20 5.85 5.40, 6.31 8.26 7.93, 8.59 7.19 6.77, 7.61 <0.0001
Self-reported Diabetes (%) 7.4 6.69, 8.10 8.76 7.33, 10.2 6.85 5.97, 7.74 10.1 8.42, 11.8 <0.01
Self reported CVD (%) 6.34 5.61, 7.08 3.66 2.60, 4.71 6.66 5.79, 7.53 6.34 5.10, 7.59 <0.0001
Medication Use (%)
Blood Pressure 22.2 20.8, 23.7 9.88 8.26, 11.5 23.4 21.7, 25.1 24.2 22.1, 26.4 <0.0001
Lipid 13.4 12.2, 14.5 6.06 4.65, 7.47 15 13.6, 16.3 8.31 6.90, 9.71 <0.0001
Diabetes 5.2 4.58, 5.82 6.12 5.00, 7.24 4.8 4.06, 5.55 7.24 5.85, 8.61 <0.01
Current smokers (%) 23.8 22.3, 25.4 19.1 16.7, 21.4 24.2 22.4, 26.1 24.8 22.2, 27.4 <0.01
Education (% College) 58 55.8, 60.2 28.1 25.0, 31.1 62.6 59.7, 65.4 50.5 47.5, 53.4 <0.0001
Values are weighted means or frequencies (%), and 95% CIs. *P values are based on Wald F-Test or Chi-square test, which test the independence of means and frequencies
across ethnic groups
a Participants sampled from November–April. b Participants sampled from May–October
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58.6 nmol/L) had a 20% relative risk reduction in MetS
[0.80 (0.66, 0.97) and the highest quartile a 27% risk re-
duction in MetS [0.73 (0.55, 0.96)] compared to the low-
est quartile. Significant associations were observed only
in the highest 25(OH)D quartile in NH-whites [0.84
(0.73, 0.95)] and NH-blacks [0.74 (0.56, 0.97)] compared
to the lowest quartile.
Serum 25(OH)D and CVD risk
In the overall sample, the relative reduction in CVD risk
was 14% in the second 25(OH)D quartile [0.86 (0.76,
0.98)], and 22% in the highest versus lowest 25(OH)D
quartile [0.78 (0.66, 0.91)] (Table 2). In ethnic-specific
analyses, significant associations were observed amongst
the highest versus lowest quartiles for NH-whites [0.78
(0.64, 0.93)] and NH-blacks [0.58 (0.41, 0.81)], but not in
MAs [0.90 (0.69, 1.16)] (Table 3).
There was a significant interaction between serum
25(OH)D and age in the CVD risk model. This is con-
sistent with the Framingham CVD risk because age is
the most heavily weighted variable in the algorithm, as
shown in Fig. 2. Therefore, we further stratified the asso-
ciation of serum 25(OH)D with CVD risk by age groups
(20–59 and ≥ 60 years). Table 4 shows the adjusted PRs
of CVD risk associated with 25(OH)D quartiles by age
category. Overall, stratification by age resulted in similar
results compared to the main model, except that the PRs
for CVD risk in participants for 20–59 years old were
lower compared to participants ≥ 60 years old. Age
stratification did not affect the observed non-significant
association of 25(OH) with CVD risk in MAs. For
NH-blacks, significant associations were attained in
participants ≥ 60 years for the highest quartile [0.63
(0.45, 0.870], but no significant association was found in
participants 20–59 years old.
Sensitivity analyses
After excluding participants with comorbid conditions,
the estimates of PRs for the adjusted associations of
25(OH)D with HOMA-IR, MetS and CVD risk remained
statistically significant (Table 2). Similarly in the ethnic-
specific analyses, the adjusted associations of 25(OH)D
with HOMA-IR, MetS and CVD risk were numerically
similar in MAs and NH-Whites after excluding partici-
pants with comorbid conditions, although the associations
were attenuated for NH-Blacks due to significant reduc-
tions in the number of events, particularly in the highest
serum 25(OH)D quartile (Table 3). Overall, the sensitivity
analyses revealed the stability of the PRs estimates in the
original models.
Discussion
In this study, we have shown that standardized serum
25(OH)D concentrations were inversely associated with
insulin resistance, MetS and CVD risk in a nationally
representative sample of U.S. adults. These associations
remained significant across all ethnic subgroups, except
for CVD risk in MAs. Overall, the results of our study
suggest that serum 25(OH)D concentrations ≥ 75 nmol/
L may be the optimal threshold in relation to cardiomet-
abolic risk. To our knowledge, this study provides the
most recently updated and comprehensive estimate of
the association between standardized serum 25(OH)D
levels and cardiometabolic risk, and unlike previous
Table 2 Prevalence ratios of cardiometaolic risk associated with serum 25(OH)D status in U.S. adults, NHANES 2001–2010
HOMAIR MetS CVD Risk
(≥15%)
Yes No PR 95% CI Yes No PR 95% CI Yes No PR 95% CI
25(OH)D quartiles (nmol/L)
< 43.4 656 1231 Ref 853 1034 Ref 487 1400 Ref
43.4–58.6 529 1365 1.02 0.89, 1.17 825 1069 1.04 0.95, 1.13 495 1399 0.86 * 0.76, 0.98
58.7–74.2 444 1528 0.89 0.76, 1.04 835 1137 1.00 0.90, 1.10 553 1419 0.90 0.79, 1.02
≥ 74.3 289 1632 0.70 * 0.59, 0.84 630 1291 0.82 * 0.74, 0.91 430 1491 0.78 * 0.66, 0.91
a Excluding those with self-reported diabetes, CVD, and taking medications (lipid, diabetes, blood
pressure)
25(OH)D quartiles (nmol/L)
< 43.4 347 890 Ref 361 876 Ref 150 1087 Ref
43.4–58.6 272 993 0.88 0.73, 1.06 350 915 0.99 0.84, 1.15 139 1126 0.85 0.64, 1.14
58.7–74.2 192 1076 0.83 0.66, 1.03 330 938 0.97 0.80, 1.17 141 1127 0.77 0.57, 1.04
≥ 74.3 108 1145 0.60 * 0.45, 0.81 193 1060 0.65 * 0.52, 0.80 119 1134 0.64 * 0.47, 0.87
Models are adjusted for age, sex, education, ethnicity, season of blood draw, survey cycle, smoking, BMI, total physical activity, vitamin D supplement use, and lipid and
anti-hyperglycemic medications
a In sensitivity analyses, models are adjusted for age, sex, education, ethnicity, season of blood draw, survey cycle, smoking, BMI, total physical activity, and vitamin D
supplement use
*P < 0.05
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Table 3 Ethnic-specific prevalence ratios for cardiometabolic risk according to serum 25(OH)D status, NHANES 2001–2010
HOMAIR MetS CVD Risk (≥15%)




< 43.4 175 346 Ref 263 258 Ref 122 399 Ref
43.4–58.6 156 445 0.9 0.70, 1.15 253 348 0.80 * 0.66, 0.97 132 469 0.85 0.66, 1.09
58.7–74.2 94 366 0.82 0.63, 1.07 188 272 0.95 0.78, 1.16 109 351 0.87 0.67, 1.14
≥ 74.3 25 187 0.54 * 0.35, 0.82 67 145 0.73 * 0.55, 0.96 45 167 0.90 0.69, 1.16
Non-Hispanic Whites
25(OH)D quartiles (nmol/L)
< 43.4 178 274 Ref 255 197 Ref 156 296 Ref
43.4–58.6 290 623 1.33 0.94, 1.36 452 461 1.07 0.95, 1.21 271 642 0.86 0.73, 1.01
58.7–74.2 314 998 0.93 0.77, 1.24 565 747 1.00 0.88, 1.14 378 934 0.88 0.75, 1.04
≥ 74.3 290 1322 0.81 * 0.68, 0.96 528 1084 0.84 * 0.73, 0.95 364 1248 0.78 * 0.64, 0.93
Non-Hispanic Blacks
25(OH)D quartiles (nmol/L)
< 43.4 246 668 Ref 327 587 Ref 209 705 Ref
43.4–58.6 80 300 0.89 0.71, 1.11 115 265 1.00 0.84, 1.19 92 288 0.83 0.65, 1.05
58.7–74.2 53 147 1.03 0.78, 1.38 78 122 1.11 0.89, 1.37 66 134 0.98 0.78, 1.23
≥ 74.3 18 79 0.67 * 0.45, 0.99 34 63 0.74 * 0.56, 0.97 21 76 0.58 * 0.41, 0.81
B Excluding participants with self-reported diabetes, CVD, and those taking relevant medications
Mexican Americans
25(OH)D quartiles (nmol/L)
< 43.4 98 273 Ref 135 236 Ref 41 330 Ref
43.4–58.6 89 343 0.99 0.72, 1.37 124 308 0.82 0.63, 1.07 32 400 0.49 * 0.29, 0.82
58.7–74.2 56 289 0.98 0.69, 1.38 106 239 1.08 0.82, 1.41 37 308 0.81 0.46, 1.44
≥ 74.3 15 143 0.53 * 0.31, 0.91 31 127 0.63 * 0.44, 0.91 17 141 1.27 0.83, 1.94
Non-Hispanic Whites
25(OH)D quartiles (nmol/L)
< 43.4 86 166 Ref 98 154 Ref 46 206 Ref
43.4–58.6 146 436 0.92 0.73, 1.19 184 398 0.98 0.79, 1.22 83 499 0.78 0.54, 1.13
58.7–74.2 124 692 0.76 * 0.58, 0.99 198 618 0.89 0.71, 1.12 92 724 0.68 * 0.47, 0.97
≥ 74.3 105 931 0.61 * 0.44, 0.83 156 880 0.61 * 0.47, 0.80 96 940 0.56 * 0.39, 0.80
Non-Hispanic Blacks
25(OH)D quartiles (nmol/L)
< 43.4 126 488 Ref 128 486 Ref 63 551 Ref
43.4–58.6 39 212 0.89 0.64, 1.24 42 209 1.05 0.77, 1.45 24 227 1.05 0.70, 1.58
58.7–74.2 19 88 1.1 0.69, 1.76 26 81 1.49 1.06, 2.10 12 95 1.26 0.66, 2.38
≥ 74.3 5 54 0.73 0.32, 1.70 6 53 0.55 0.25, 1.21 6 53 0.72 0.33, 1.58
Models are adjusted for age, sex, education, season of blood draw, survey cycle, smoking, BMI, total physical activity, vitamin D supplement use, and lipid and
anti-hyperglycemic medications. *P < 0.05
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studies, our findings demonstrate that low 25(OH)D is a
significant risk factor for cardiometabolic risk in U.S.
blacks.
The inverse associations between vitamin D status and
insulin resistance, MetS and CVD risk are aligned with
previous epidemiologic studies. Of note, previous ana-
lyses of NHANES have found an inverse association be-
tween unstandardized serum 25(OH)D levels with
insulin resistance and pre-diabetes [11, 38], MetS [4],
and CVD mortality [39]. Similarly, prospective studies
have shown an inverse association between serum
25(OH)D and insulin resistance [40] and incident CVD
in the Framingham Offspring Study [5], and incidence of
MetS in a cohort of non-diabetic adults [8].
Previous studies have shown ethnic differences in the
association of serum 25(OH)D with cardiometabolic risk
factors. Ethnic differences between serum 25(OH)D and
risk of diabetes were found in NHANES III [22], and
confirmed in NHANES 2001–2006 with significant
inverse associations in MAs and NH-whites, but not in
NH-Blacks [23]. In a prospective study, Robinson-Cohen
et al. [25] reported a significant increase in the risk of
coronary heart disease events with low 25(OH)D levels
in whites and Chinese, but not in black or Hispanic par-
ticipants from the Multi-Ethnic Study of Atherosclerosis.
Lutsey et al. [41] also observed that low 25(OH)D levels
were a stronger risk factor for the development of heart
failure in whites than black participants from the Ath-
erosclerosis Risk in Communities study. Conversely, our
results showed a significant inverse association of stan-
dardized 25(OH)D with cardiometabolic risk in MAs,
NH-Whites, and NH-blacks.
Our results are in contrast to the vitamin D paradox
observed in blacks, where prior studies have suggested
that even though blacks have circulating 25(OH)D in the
deficient range (<50 nmol/L), a compensatory mechan-
ism exists in relation to bone health [42, 43]. At this
time, it is not fully understood whether other
Fig. 2 Prevalence of cardiovascular disease risk (≥15%) by age status in participants≥ 20 years, NHANES 2001–2010. *P < 0.05




Q1 (<43.4) Q2 (43.4–58.6) Q3 (58.7–74.2) Q4 (≥74.3)
Overall 20–59 (y) Ref 0.78 0.60, 1.02 0.93 0.70, 1.23 0.65* 0.47, 0.92
≥60 (y) Ref 0.99 0.89, 1.09 0.89* 0.80, 0.99 0.82* 0.73, 0.92
a Mexican Americans 20–59 (y) Ref 0.70 0.49, 1.01 0.80 0.50, 1.27 0.75 0.44, 1.29
≥60 (y) Ref 0.93 0.79, 1.10 0.92 0.78, 1.08 0.81 0.63, 1.03
a Non-Hispanic Whites 20–59 (y) Ref 0.70 0.48, 1.02 0.89 0.62, 1.29 0.61* 0.40, 0.93
≥60 (y) Ref 1.01 0.88, 1.16 0.90 0.79, 1.04 0.82* 0.74, 0.97
a Non-Hispanic Blacks 20–59 (y) Ref 1.03 0.75, 1.43 0.97 0.69, 1.37 0.51 0.19, 1.40
≥60 (y) Ref 0.88 0.75, 1.04 0.86 0.71, 1.04 0.63* 0.45, 0.88
Models are adjusted for age, sex, education, ethnicity, season of blood draw, survey cycle, smoking, BMI, total physical activity
vitamin D supplement use, and lipid and anti-hyperglycemic medications. *P < 0.05
a The ethnicity covariate is excluded in the ethnic-specific models
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compensatory mechanisms exist in relation to cardiovas-
cular health outcomes, but it has been speculated that
vitamin D binding protein (DBP) levels in blacks are sig-
nificantly lower compared to whites to compensate for
lower total serum 25(OH)D in blacks. It has also been
suggested that total 25(OH)D may not be the best bio-
marker of vitamin D status in blacks [44]. However, the
monoclonal immunoassay used by Powe et al. [44] has
been criticized for its lack of sensitivity to DBP polymor-
phisms, which provides erroneous results for vitamin D
metabolites [45]. Using a novel LC-MS/MS method,
Henderson et al. [46] recently showed that levels of DBP
do not vary between whites and blacks. Therefore, it is
possible that the use of immunoassays in a population
with a low range of vitamin D metabolites results in in-
accurate total 25(OH)D concentrations in blacks and
that the results from existing immunoassays might be
insufficient to allow identification of a significant associ-
ation within these populations.
Previous attempts to assess the ethnic-specific associ-
ation between cardiometabolic disorders and 25(OH)D
have been limited due to reliance on samples with a low
number of blacks within the upper range of 25(OH)D
concentrations (i.e. ≥ 75 nmol/L). In comparison with
prior work, our results suggest significant risk reductions
in NH-blacks, which we speculate is due to reduced
variation from the standardization of 25(OH)D measure-
ments across all NHANES survey cycles [30]. Moreover,
the lowest levels of 25(OH)D were observed in NH-
blacks in our study, supporting the hypothesis that black
Americans have reduced cutaneous synthesis of vitamin
D due to increased skin pigmentation and decreased sun
exposure [47]. In support of this hypothesis, Alzaman et
al. [48] did not observe any systemic difference in the
absorption or bioavailability of oral vitamin D metabo-
lites between US blacks and whites, neither do their re-
sults support the paradoxical clinical correlates of
vitamin D in US blacks [48]. Taken together, our results
add to the current evidence by demonstrating that total
circulating 25(OH)D is a significant biomarker of cardio-
metabolic risk in U.S. blacks.
Although mechanisms relating vitamin D deficiency
and cardiometabolic risk factors are not fully elucidated,
several important mechanisms warrant discussion. Insu-
lin resistance is the core trait of the metabolic distur-
bances observed in MetS, type-2 diabetes and CVD risk
[49]. The presence of vitamin D receptors (VDRs) in
pancreatic β-cells suggest that the active metabolite 1-α-
25-dihydroxyvitamin D3 (1,25(OH)2D3) could directly
influence insulin secretion [50]. Since insulin secretion is
a calcium dependent process, it is possible that
1,25(OH)2D3 modulates insulin secretion by increasing
intracellular calcium levels [50]. Moreover, vitamin D
deficiency promotes secondary hyperparathyroidism,
stimulates the RAAS, which in turn increases the secre-
tion of aldosterone [51]. Both low serum 25(OH)D and
high PTH levels are related to arterial stiffness and
vascular dysfunction, which are significant elements of
hypertension and CVD risk [52]. It is possible that lower
25(OH)D and higher serum PTH levels could synergis-
tically or independently play a role in the pathogenesis
of developing hypertension and future CVD [53]. Due to
the lack of data in our study, we were not able to eluci-
date the role of PTH in our analyses, however, the exclu-
sion of participants with eGFR < 60 mL/min/1.73 m2
reduces the potential confounding of secondary hyper-
parathyroidism caused by chronic renal failure and the
impaired vitamin D metabolism by the diseased kidneys.
Future studies using standardized serum 25(OH)D data
are needed to re-evaluate the optimal 25(OH)D thresh-
olds that maximally suppress PTH levels [54]. The com-
plexity of vitamin D and PTH metabolism makes it
challenging to fully disentangle the individual contribu-
tions of these factors and warrants further investigation.
In addition, the relationship between vitamin D defi-
ciency and metabolic traits of these diseases is con-
founded by adiposity where individuals with obesity have
lower serum 25(OH)D levels compared to normal-
weight individuals and this is consistent across different
age and ethnic groups [55–58]. Hence, serum 25(OH)D
concentrations are related to fat mass and changes in
serum PTH, and adipokines, such as leptin and adipo-
nectin, may be crucial in elucidating the relationship
between vitamin D, PTH and metabolic disturbances
[59, 60]. It is possible that normal vitamin D metabolism
may be disrupted in obesity due to elevated levels of
serum leptin, which has been shown to suppress the
conversion of 25(OH)D to 1,25(OH)2D3 [61]. Although
we were not able to further adjust for leptin levels, we
adjusted for BMI, which is a proxy for fat mass and lep-
tin levels [62]. Moreover, given that obesity and meta-
bolic diseases are associated with low-grade inflammation,
the anti-inflammatory and immunomodulatory properties
of vitamin D have been suggested and supported by previ-
ous studies showing an inverse, but inconsistent, relation-
ship between vitamin D and inflammatory markers such
as C-reactive protein (CRP) [63–65]. A recent Mendelian
randomization study found no causal relationship between
vitamin D and CRP [66], which suggests that it is unlikely
that vitamin D deficiency directly contributes to increased
inflammation or vice versa. In our study, we found no evi-
dence of the potential confounding effect of CRP levels on
the relationship between serum 25(OH)D and all outcome
measures (data not shown). Taken together, experimental
and observational studies suggest that the relationship
between vitamin D and cardiometabolic disorders are
multimodal and mediated through direct and indirect
pathways. Further, it is important that the results of this
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study are interpreted according to variation in vitamin D
metabolism genes, which could explain the heterogen-
eity of responses to vitamin D deficiency across eth-
nic groups [67].
Although the evidence from previous observational
studies and our results suggest that serum 25(OH)D
levels ≥ 75 nmol/L are associated with lower risk of car-
diometabolic disorders compared to 25(OH)D ≤ 50 nmol/
L, these findings have not been consistent in clinical trials
[68–71]. Among the possible explanations for these differ-
ences include the substantial heterogeneity in the defin-
ition of vitamin D deficiency, different age structure and
target population (i.e., vitamin D deficient versus sufficient
individuals), primary versus secondary prevention of
CVD, differences in the available assays used to measure
vitamin D metabolites, as well as the inclusion of different
confounders in their analyses. Although the relationship
between optimal vitamin D status and cardiovascular
health remains to be elucidated, the standardization of
serum 25(OH)D data and the large sample size of our
study allowed a comprehensive estimate of the association
between 25(OH)D and cardiometabolic risk in US adults
using a nationally representative survey sample. Given that
many risk factors for CVD are clustered in insulin resist-
ance and MetS, it is reasonable to speculate that low
25(OH)D is a significant risk factor in their development,
which may ultimately contribute to increased CVD risk.
Future studies must be sufficiently powered to estimate
the overall benefit, as well as study the risks and benefits
associated with varying circulating 25(OH)D concentra-
tions in ethnic subpopulations.
There are several limitations to this study. Due to the
cross-sectional design, we are unable to rule out the pos-
sibility of reverse causation. Although we have adjusted
for potential confounders, we cannot rule out residual
confounding or the effect of unmeasured confounders.
Further, seasonality of serum 25(OH)D levels in
NHANES must be considered a confounder because of
the sampling design wherein data is collected from
northern states in the summer and southern states in
the winter. This sampling design results in higher
average 25(OH)D and an increased range of 25(OH)D
concentrations in northern states. Despite these limita-
tions, our study provides national estimates of the associ-
ation between serum 25(OH)D and cardiometabolic risk
in the U.S. population and in ethnic subgroups using stan-
dardized serum 25(OH)D data from 2001–2010.
Conclusions
In this large national sample, standardized serum
25(OH)D concentrations were significantly associated
with cardiometabolic risk including insulin resistance,
MetS and CVD risk in U.S. adults, and low 25(OH)D is
a significant risk factor for cardiometabolic risk in MAs,
NH-whites, and NH-blacks. Standardization of serum
25(OH)D allows accurate assessment of vitamin D sta-
tus, and future studies are needed to re-evaluate these
risks in black Americans with serum 25(OH)D concen-
trations above 75 nmol/L.
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